Gene Sackett1, Alan Unis, Brenda Crouthamel. 1. Infant Primate Research Laboratory, University of Washington, National Primate Research Center, Seattle, Washington 98195, USA. jsackett@Wanprc.org
Abstract
OBJECTIVE: Atypical antipsychotic drugs are prescribed to young children for a number of symptoms, some with no Food and Drug Administration approval for children. Effects on growth of children have received little experimental study. We assessed the effects of two atypicals, risperidone and quetiapine, on growth, prolactin, and thyroid hormones of young pigtail macaques (macaca nemestrina), modeling potential effects on 4-8-year-old children. METHODS: Subjects were studied blindly after random assignment to risperidone (N = 10), quetiapine (N = 10), or placebo (N = 20). Four phases were studied: (1) predrug, 9-12 months of age; (2) low dose (risperidone 0.025 mg/kg, quetiapine 2 mg/kg), 13-16 months; (3) high dose (risperidone 0.05 mg/kg, quetiapine 4 mg/kg), 17-20 months; (4) postdrug, 21-24 months. Body weight was measured daily, skeletal dimension monthly, and bone mineralization and hormones bimonthly. RESULTS: Our primary result showed that, compared with placebo, neither drug had detrimental effects on body weight, skeletal dimensions, or thyroid hormones. However, in a transient effect, bone density was lower following low-dose risperidone than either quetiapine or placebo. In both drug phases, risperidone prolactin was higher than the other groups, which did not differ. The higher prolactin of the risperidone group may partially explain the bone density effect. CONCLUSION: This 16-month study of young, developing pigtail macaques given risperidone at doses from 0.025 to 0.05 mg/kg or quetiapine at doses from 2 to 4 mg/kg suggests that these drugs are safe for normal body weight and skeletal growth in young pigtail macaques given an adequate diet, although these drugs are known to cause significant weight gain and other metabolic changes in some children, adolescents, and adult humans. In addition, the results, although transient in our study, also suggest that research in children on bone mineralization effects of risperidone, and possibly other antipsychotic drugs, may be warranted.
RCT Entities:
OBJECTIVE: Atypical antipsychotic drugs are prescribed to young children for a number of symptoms, some with no Food and Drug Administration approval for children. Effects on growth of children have received little experimental study. We assessed the effects of two atypicals, risperidone and quetiapine, on growth, prolactin, and thyroid hormones of young pigtail macaques (macaca nemestrina), modeling potential effects on 4-8-year-old children. METHODS: Subjects were studied blindly after random assignment to risperidone (N = 10), quetiapine (N = 10), or placebo (N = 20). Four phases were studied: (1) predrug, 9-12 months of age; (2) low dose (risperidone 0.025 mg/kg, quetiapine 2 mg/kg), 13-16 months; (3) high dose (risperidone 0.05 mg/kg, quetiapine 4 mg/kg), 17-20 months; (4) postdrug, 21-24 months. Body weight was measured daily, skeletal dimension monthly, and bone mineralization and hormones bimonthly. RESULTS: Our primary result showed that, compared with placebo, neither drug had detrimental effects on body weight, skeletal dimensions, or thyroid hormones. However, in a transient effect, bone density was lower following low-dose risperidone than either quetiapine or placebo. In both drug phases, risperidoneprolactin was higher than the other groups, which did not differ. The higher prolactin of the risperidone group may partially explain the bone density effect. CONCLUSION: This 16-month study of young, developing pigtail macaques given risperidone at doses from 0.025 to 0.05 mg/kg or quetiapine at doses from 2 to 4 mg/kg suggests that these drugs are safe for normal body weight and skeletal growth in young pigtail macaques given an adequate diet, although these drugs are known to cause significant weight gain and other metabolic changes in some children, adolescents, and adult humans. In addition, the results, although transient in our study, also suggest that research in children on bone mineralization effects of risperidone, and possibly other antipsychotic drugs, may be warranted.
Authors: George Abraham; Wynn Wynn Paing; Joanne Kaminski; Ashok Joseph; Eva Kohegyi; Richard C Josiassen Journal: Am J Psychiatry Date: 2003-09 Impact factor: 18.112
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Linmarie Sikich; Jean A Frazier; Jon McClellan; Robert L Findling; Benedetto Vitiello; Louise Ritz; Denisse Ambler; Madeline Puglia; Ann E Maloney; Emily Michael; Sandra De Jong; Karen Slifka; Nancy Noyes; Stefanie Hlastala; Leslie Pierson; Nora K McNamara; Denise Delporto-Bedoya; Robert Anderson; Robert M Hamer; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2008-09-15 Impact factor: 18.112
Authors: Magali Haas; Alan S Unis; Jorge Armenteros; Margaret D Copenhaver; Jorge A Quiroz; Stuart F Kushner Journal: J Child Adolesc Psychopharmacol Date: 2009-12 Impact factor: 2.576
Authors: Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte Journal: Ther Adv Psychopharmacol Date: 2013-10
Authors: Chadi A Calarge; James A Mills; Lefkothea Karaviti; Antonio L Teixeira; Babette S Zemel; Jose M Garcia Journal: J Pediatr Date: 2018-06-27 Impact factor: 4.406
Authors: Thomas M Burbacher; Kimberly S Grant; Julie Worlein; James Ha; Eliza Curnow; Sandra Juul; Gene P Sackett Journal: Am J Primatol Date: 2013-07-19 Impact factor: 2.371
Authors: Mark E Bardgett; Julie M Franks-Henry; Kristin R Colemire; Kathleen R Juneau; Rachel M Stevens; Cecile A Marczinski; Molly S Griffith Journal: Exp Clin Psychopharmacol Date: 2013-06 Impact factor: 3.157